Published in Stem Cells on June 01, 2010
Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres. Cell Cycle (2012) 1.14
Profiling of normal and malignant breast tissue show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers. BMC Cancer (2013) 0.97
Identification of specific cell-surface markers of adipose-derived stem cells from subcutaneous and visceral fat depots. Stem Cell Reports (2014) 0.96
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 0.95
Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response. Stem Cell Reports (2015) 0.93
Quantification of regenerative potential in primary human mammary epithelial cells. Development (2015) 0.93
In vitro analysis of breast cancer cell line tumourspheres and primary human breast epithelia mammospheres demonstrates inter- and intrasphere heterogeneity. PLoS One (2013) 0.92
Role of microRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells. Oncotarget (2015) 0.88
Is mammary not otherwise specified-type sarcoma with CD10 expression a distinct entity? A rare case report with immunohistochemical and ultrastructural study. Diagn Pathol (2013) 0.86
Extracellular molecules involved in cancer cell invasion. Cancers (Basel) (2015) 0.85
Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease. Oncotarget (2014) 0.84
ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas. Oncotarget (2015) 0.83
Cancer stem cells in breast cancer. Cancers (Basel) (2011) 0.80
Overexpression of Id1 in transgenic mice promotes mammary basal stem cell activity and breast tumorigenesis. Oncotarget (2015) 0.79
Long-term exposure to bisphenol A or benzo(a)pyrene alters the fate of human mammary epithelial stem cells in response to BMP2 and BMP4, by pre-activating BMP signaling. Cell Death Differ (2016) 0.79
Pleiotrophin (PTN) expression and function and in the mouse mammary gland and mammary epithelial cells. PLoS One (2012) 0.78
CD10: a tool to crack the role of stem cells in breast cancer. Proc Natl Acad Sci U S A (2011) 0.77
Distribution of CD10-positive epithelial and mesenchymal cells in human mid-term fetuses: a comparison with CD34 expression. Anat Cell Biol (2014) 0.75
HER2-Positive Metaplastic Spindle Cell Carcinoma Associated with Synchronous Bilateral Apocrine Carcinoma of the Breast. Case Rep Pathol (2014) 0.75
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. Stem Cell Reports (2017) 0.75
Comparison of immunohistochemical expression of CD10 in keratocystic odontogenic tumor and ameloblastoma. Dent Res J (Isfahan) (2016) 0.75
Immunohistochemical expression of Fas ligand (FasL) and neprilysin (neutral endopeptidase/CD10) in keratoconus. Int Ophthalmol (2012) 0.75
Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 8.97
Metastasis: a question of life or death. Nat Rev Cancer (2006) 6.26
Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell (2008) 5.88
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
Retracted Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol (2009) 3.84
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
The oncologic outcome and immediate surgical complications of lipofilling in breast cancer patients: a multicenter study--Milan-Paris-Lyon experience of 646 lipofilling procedures. Plast Reconstr Surg (2011) 2.51
A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell (2013) 2.46
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol (2003) 2.05
Human telomeric position effect is determined by chromosomal context and telomeric chromatin integrity. EMBO Rep (2002) 1.79
Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell (2004) 1.71
Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet (2009) 1.55
Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. Leuk Res (2010) 1.54
Influence of neuroblastoma stage on serum-based detection of MYCN amplification. Pediatr Blood Cancer (2009) 1.49
EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet (2012) 1.47
Gadd45a activation protects melanoma cells from ultraviolet B-induced apoptosis. J Invest Dermatol (2007) 1.47
A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. Int J Cancer (2006) 1.44
MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. Cancer Res (2002) 1.41
Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol (2013) 1.40
Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med (2009) 1.36
p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. Cancer Cell (2013) 1.35
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res (2012) 1.26
Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene (2003) 1.25
Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. Hum Mutat (2006) 1.25
Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem (2009) 1.17
p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol (2006) 1.14
BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood (2008) 1.10
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat (2011) 1.04
p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene (2004) 1.04
Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type. Hum Genet (2002) 1.03
Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res (2002) 1.02
PLA2R1 mediates tumor suppression by activating JAK2. Cancer Res (2013) 1.01
The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells. J Cell Sci (2005) 0.99
Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation. Hum Mutat (2007) 0.99
Percutaneous fasciotomies and fat grafting: indications for breast surgery. Aesthet Surg J (2013) 0.99
The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells. Oncogene (2005) 0.98
Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function. Oncogene (2002) 0.97
Methylome analysis reveals Jak-STAT pathway deregulation in putative breast cancer stem cells. Epigenetics (2011) 0.97
TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma. PLoS One (2012) 0.96
Radiographic findings after breast augmentation by autologous fat transfer. Plast Reconstr Surg (2011) 0.94
BTG2, its family and its tutor. Bull Cancer (2004) 0.94
The tumor suppressor gene TP53: implications for cancer management and therapy. Crit Rev Clin Lab Sci (2004) 0.94
Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma. J Clin Oncol (2005) 0.93
The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene (2002) 0.93
Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol (2013) 0.92
Genome-wide analysis of gene expression in neuroblastomas detected by mass screening. Cancer Lett (2004) 0.92
BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells. Oncogene (2002) 0.91
Mutational targets in colorectal cancer cells with microsatellite instability. Fam Cancer (2006) 0.91
Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett (2005) 0.90
Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis (2010) 0.89
Chfr inactivation is not associated to chromosomal instability in colon cancers. Oncogene (2003) 0.89
Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression. Blood (2013) 0.89
Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behavior after the disclosure of a positive test result. Cancer Epidemiol Biomarkers Prev (2002) 0.88
TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Miner Res (2014) 0.88
Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells. J Immunother (2010) 0.88
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica (2013) 0.88
Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer (2008) 0.87
PLA2R1 kills cancer cells by inducing mitochondrial stress. Free Radic Biol Med (2013) 0.87
Failsafe program escape and EMT: a deleterious partnership. Semin Cancer Biol (2011) 0.87
Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood (2010) 0.87
CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. Blood (2011) 0.86
Variants in the netrin-1 receptor UNC5C prevent apoptosis and increase risk of familial colorectal cancer. Gastroenterology (2011) 0.86
Breast fat grafting (lipomodelling) after extended latissimus dorsi flap breast reconstruction: a preliminary report of 200 consecutive cases. J Plast Reconstr Aesthet Surg (2010) 0.85
Copper isotope effect in serum of cancer patients. A pilot study. Metallomics (2015) 0.84
FLRG, a new ADAM12-associated protein, modulates osteoclast differentiation. Biol Cell (2005) 0.84
Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer (2002) 0.84
Intensity-dependent constitutional MLH1 promoter methylation leads to early onset of colorectal cancer by affecting both alleles. Genes Chromosomes Cancer (2010) 0.84
Tif1γ is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Development (2012) 0.84
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer (2006) 0.84
The SNAIL family member SCRATCH1 is not expressed in human tumors. Oncol Rep (2010) 0.83
TP63 gene in stress response and carcinogenesis: a broader role than expected. Bull Cancer (2006) 0.83
In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. Carcinogenesis (2007) 0.83
Caspase-dependent BRCA1 cleavage facilitates chemotherapy-induced apoptosis. Apoptosis (2008) 0.83
Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine. Biochem Pharmacol (2003) 0.82
Early origin of cancer metastases: dissemination and evolution of premalignant cells. Cell Cycle (2008) 0.82
Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms. Hum Mutat (2002) 0.82
UVB-induced G2 arrest of human melanocytes involves Cdc2 sequestration by Gadd45a in nuclear speckles. Cell Cycle (2006) 0.82
Breast asymmetry and pectus excavatum improvement with fat grafting. Aesthet Surg J (2013) 0.81
Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. Leuk Res (2010) 0.80
Interhelical loops within the bHLH domain are determinant in maintaining TWIST1-DNA complexes. J Biomol Struct Dyn (2013) 0.80
[BMP and cancer: the Yin and Yang of stem cells]. Med Sci (Paris) (2012) 0.80
ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells. Mol Cancer (2014) 0.80
A protocol to quantify mammary early common progenitors from long-term mammosphere culture. Curr Protoc Stem Cell Biol (2012) 0.79
Determinants of hypertension control in a large French population of treated hypertensive subjects. Blood Press (2006) 0.79